Foresight Diagnostics was founded by four Stanford University physicians and scientists who sought to develop high-performing circulating tumor DNA (ctDNA) assays by improving the limits of detection through innovative techniques and enhanced bioinformatics. Our product, Foresight CLARITY™, utilizes a proprietary and patented phased variant (PV) detection method to improve the accuracy of ctDNA tests and minimal residual disease (MRD) measurement. Foresight Diagnostics was acquired by Natera in December 2025 and operates a CLIA laboratory in Boulder, Colorado.
| Website | https://www.foresight-dx.com/ |
| Revenue | $6.8 million |
| Employees | 110 (82 on RocketReach) |
| Founded | 2020 |
| Industry | Biotechnology Research |
| Keywords | Minimal Residual Disease, Liquid Biopsy, Precision Medicine, Cancer Diagnostics, Molecular Diagnostics, Oncology Diagnostics, Early Cancer Detection, Disease Monitoring, Patient Management, Cancer Treatment, Biomarker Discovery, Diagnostic Testing, In-Vitro Diagnostics, Ivd Testing, Medical Diagnostics, Novel Diagnostics, Healthcare Diagnostics, Clinical Diagnostics |
| Competitors | Thermo Fisher Scientific, Exact Sciences, Guardant Health, GRAIL, Myriad Genetics, Foundation Medicine, Caris Life Sciences, NeoGenomics Laboratories, Invitae, Biocept, Inc. +35 more (view full list) |
Looking for a particular Foresight Diagnostics Inc. employee's phone or email?
The Foresight Diagnostics Inc. annual revenue was $6.8 million in 2026.
Jake Chabon is the Co-founder and CEO of Foresight Diagnostics Inc..
82 people are employed at Foresight Diagnostics Inc..
Foresight Diagnostics Inc. is based in Boulder, Colorado.